CEL-SCI Corporation (CEL-SCI) is a research and development company focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The Company is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. Its investigational immunotherapy is Multikine (Leukocyte Interleukin, Injection). The Company also owns and is developing a pre-clinical technology called Ligand Epitope Antigen Presentation System (LEAPS). The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. The Company�s Multikine, is being developed for the treatment of cancer. LEAPS is designed to stimulate the human immune system to effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own.